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Abstract Acute lymphoblastic leukemia is one of the
malignant proliferations of lymphoid cells in the early
stages of differentiation and accounts for about 80% of all
cases of childhood leukemia. Side effects of available
treatment are still main concern. Thymoquinone (TQ), a
natural compound isolated from Nigella sativa, induces
growth inhibition and apoptosis in several cancer cell lines.
The aim of the present study was to investigate the effect of
TQ alone and in combination with doxorubicine on the
proliferation inhibition and apoptosis induction of TQ in a
lymphoblastic leukemia cell line. Jurkat cell line was cul-
tured in standard condition and with concentrations of TQ
(0–30 lm) and doxorubicine for 24, 48 and 72 h. Cell
viability was measured by MTS assay. Apoptosis induction
by TQ was assessed by annexin V-FITC/PI and flow
cytometry analysis. TQ and DOX decreased cell viability
with a time and dose dependent manner. The IC50 values
were 19.461 ± 1.141, 17.342 ± 1.949 and 14.123 ±
1.874 lM in 24, 48 and 72 h, respectively for TQ. IC50
values for DOX were. 075 ± .0124, .028 ± .007
and.007 ± .001 lM in 24, 48 and 72 h, respectively. The
level of cell apoptosis in all used concentrations of TQ (4,
8, 12, 16 and 20 lm) was higher than control group (10.2,
14.1, 36.6, 87.5 and 93.3% respectively after 24 h; 10.7,
13.9, 64.6, 92.2 and 93.1 respectively after 48 h; 2.83, 5.83,
41.4, 71.6 and 86.6% respectively after 72 h) and reached
to a significant level at 12, 16 and 20 lm concentration for
24 and 48 h and 16 and 20 lm for 72 h incubation.
Combination of doxorubicine and TQ lead to a synergistic
cytotoxicity as compared to any of them alone. The study
indicated that TQ is effective on proliferation inhibition
and is a strong apoptotic inducer in Jurkat lymphoblastic
cell line and has synergistic effect in combination with
DOX. This combination strategy can be an alternative way
for more powerful anticancer effects. Therefore, the study
of the mechanism of apoptosis induction of TQ can be a
step forward to in target therapy which might be considered
in the future studies.
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Introduction
Leukemias are heterogeneous malignancies [1], comprise
8% of cancers. About 80% of children leukemia cases are
acute lymphoblastic leukemia [2]. Acute lymphoblastic
leukemia is a malignant expansion of lymphoid precursor
cells within the bone marrow, blood and extra medullary
location [3], influences both children and adolescence, with
a peak between the ages of 2 and 5 years and again after
age of 50 [4]. Patients with T cell acute lymphoblastic
leukemia (T-ALL) experience a higher recurrence and
early relapse [5]. Intensification the treatment to promote
survival prompts the patients to more unfavorable effects
[6]. This fact derived us to new therapeutic target for the
disease [5]. Over the recent years, there has been
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developing interest for naturally phytochemical compo-
nents. Studies showed a regimen rich in phytochemical
mixes find in plant and natural products (such as vegeta-
bles, blooms, entire grains, herbs, nuts, and seeds) are
linked with cancer prevention and treatment. More than
25% of medications utilized during the last 20 years are
straightforwardly gotten from plants, while the other 25%
are artificially modified natural products [7]. Thymo-
quinone (2-isopropyl-5-methyl-1,4-benzoquinone), is a
phytochemical compound derived from the plant Nigella
sativa or black cumin, which is utilized widely by Middle
and Far Eastern nations [8, 9]. Different studies have
exhibited that thymoquinone (TQ) has several therapeutic
effects including: anti-bacterial, anti-parasitic, anti-viral,
anti-inflammatory, immunomodulatory and anti-tumor
properties [8, 9] and acts as an intense cytotoxic drug over
a variety of human cancer cells [10] such as human breast
and ovarian adenocarcinoma [11] squamous carcinoma
[12], fibrosarcoma [12], laryngeal neoplastic cells [13],
prostate and pancreatic cancer (PC) cell lines [14–17]. It
has been recommended that TQ, as a DNA damaging
factor, is a possible reactive oxygen species (ROS) pro-
ducer which applies its anti-cancer properties by repressing
cell growth, migration, invasion, angiogenesis and induc-
tion of apoptosis [18, 19]. The proliferation inhibitory
effects of TQ is specific to cancer cells while it is less
noxious to and keeps non-tumor normal cells from
chemotherapy-induced damage [10, 20].
Apoptosis, also named as endogenous programmed cell
death, is a basic pathway for controlling homeostasis and
morphogenesis and involves in pathogens of cancers [21].
Induction of apoptosis is the most important mechanism of
action in anticancer agents and its defect not only leads to
progression of tumors but also increases their resistance to
treatment [22, 23]. Thus, promoting apoptosis in tumors is
one of the best ways for anticancer treatments [24]. We
have recently reported the anti-proliferative and apoptosis
effects of Pterostilbene, a phytonutrients, on T-cell lym-
phoblastic leukemia cell (jurkat) [25], here we examined
the anti-proliferative and apoptosis induction of TQ on this
cell line.
Materials and Methods
Cell Culture and Treatment
The human T-cell leukemia line (Jurkat, E6.1) was cultured
in standard condition (95% humidity, 5% CO2, 37 C) in
RPMI 1640 supplemented with 10% heat-inactivated fetal
bovine serum (FBS), 100 IU/mL penicillin, 0.1 mg/mL
streptomycin (PS) and 0.3 mg/ml L-glutamine. A 200 mM
solution of TQ (Sigma-Aldrich) and DOX (Sigma-Aldrich)
was prepared in 100% DMSO (DiMethylSulfOxide,
Sigma-Aldrich) and appropriate working concentrations
were prepared with the cell culture medium; the final
concentration of DMSO was less than 0.1% in both control
and treated cells.
Cell Viability Assay
Jurkat cells were seeded in a concentration of 10 9 103 cells
per well in 96-well plates for 24 h before treatment and
exposed to TQ and DOX at different concentrations
(0–30 lM), (0–0.2 lM), respectively, for different periods.
Cell viability was then examined by colorimetric assay using
the CellTiter 96 Aqueous One Solution Cell Proliferation
Assay (MTS), according to manufacturer’s instruction (Pro-
mega, USA). Briefly 20 lL of MTS (5 mg/mL in phosphate
buffered saline) was added to each well and incubated for 3 h,
in a dark place. The absorbance was measured at 490–620 nm
by an Elisa reader (stat fax-2100 awarenes).
Apoptosis Assay
Cells were seeded in 6-well plates at a density of
2 9 106 cells per well, grown for 24 h before treatment
with TQ at different concentrations for 24, 48 and 72 h.
The apoptosis was examined by flow cytometry (Partec
system, Germany) using the Annexin V-FITC/propidium
iodide (PI) apoptosis kit (BD Biosciences), according to
manufacturer’s instruction. Briefly cells were washed twice
with cold PBS, then cells resuspended in 1 ml of
1 9 binding buffer (provided with kit) at density of
10 9 105 100 lL of cell suspension incubated with 5 ll of
Annexin V-FITC and PI for 15 min at dark at room tem-
perature, then examined by flow cytometry. Flowjo 7.6
software was used for the analysis of the data. At least
10,000 events were recorded and represented as dot plots
and histograms.
Cytotoxicity Assay for the Combination
of Thymoquinone and Doxorubicine
Jurkat cells were seeded in 96 well plate at a density of
10 9 103 for 24 h before treatment. TQ and DOX were
added at specific concentrations, and cells were incubated
for 24, 48 and 72 h. Cell viability assay was performed as
described above. Synergistic effect was determined by
combination-index methods, derived from the median
effect principle of Chou and Talalay [26] using the fol-
lowing formula: CI = CA,50/IC50,A ? CB,50/IC50,B. CA,50
and CB,50: were the concentrations of drug A and drug B
used in combination to achieve 50% drug effect; IC50,A and
IC50,B were the concentrations of individual agents to
achieve the 50% drug effect. The combination-index (CI)
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method is a mathematical and quantitative representation
of a two-drug pharmacologic interaction. A CI of 1 indi-
cated an additive effect between the two agents, whereas a
CI\ 1 or CI[ 1 indicated, synergism or antagonism
effect, respectively.
Statistical Analysis
Data were analyzed by SPSS using Kruskal–Wallis test and
are presented as the mean ± standard deviation from at
least three independent experiments. IC50 value was cal-
culated using probit analysis.
Results
Reduction of Cell Viability by TQ
To determine the effect of TQ on viability of Jurkat cells,
cells were incubated for 24, 48 and 72 h in the absence or
presence of TQ at different concentrations (0–30 lM). The
ODs obtained from the absorption at 490 nm was con-
verted to a percentage. Figure 1 shows the reduction of cell
viability as concentration increased (dose-dependent). A
significant reduction of Jurkat cell viability was also
observed with a time-dependent manner at a specific con-
centration. IC50 (inhibition concentration) was
19.461 ± 1.141, 17.342 ± 1.949 and 14.123 ± 1.874 lM
in 24, 48 and 72 h, respectively.
Reduction of Cell Viability by DOX
Jurkat cells, cells were incubated for 24, 48 and 72 h in the
absence or presence of DOX at different concentrations (0–
.2 lM). Figure 2 shows the reduction of cell viability as
concentration increased (dose-dependent). The reduction of
viability was also time dependent. IC50 values were
0.075 ± .0124, .028 ± .007 and .007 ± .001 lM in 24, 48
and 72 h, respectively.
Induction of Apoptosis by TQ
To assess whether TQ could induce apoptosis in Jurkat
cells, apoptosis induction was determined by annexin-V/PI
apoptosis detection kit. Cells were incubated for 24, 48 and
72 h at various concentrations (4, 8, 12, 16, and 20 lM) of
TQ. Cells that were positive just for annexin-V and those
were positive both for annexin V and PI considered as early
and late apoptotic cells, respectively. As shown in Fig. 3,
amount of apoptotic cells are enhanced with increasing the
concentration of TQ. After 48 h treatment with above
concentrations, about 5.6, 2.15, 6.4, 6.45 and 3.3% of cells
were early apoptotic cells and 4.81, 11.5, 57.9, 85.6 and
89.6% of cells were late apoptotic cells, Fig. 4, shows the
continuous process of apoptosis. The other two time groups
(24 and 72 h) showed this continuous process (data not
illustrated). These data showed a significant increase in the
number of apoptotic cells post treatment (P\ 0.05 con-
sidered significant) (Fig. 5).
As shown in Fig. 5, TQ lead to increase amount of
apoptotic cell and the difference are significant at 3 con-
centrations (12, 16 and 20 lM) for 24 and 48 h and 2
concentrations (16 and 20 lM) for 72 h, compared to
control. Also in each group, different concentrations were
compared to each other, and were significant at 4 and 16
(P\ 0.05), 4 and 20 (P\ 0.01), 8 and 20 lM (P\ 0.05)
for 24, 48 and 72 h, respectively.
Synergistic Effect of TQ and DOX
Cell viability was evaluated in the presence of different
combinations of TQ and DOX. Stronger cytotoxicity was
Fig. 1 Effect of TQ on Jurkat cell viability by MTS assay. Cells were
incubated with different concentrations of TQ for 24, 48 and 72 h and
cell viability was determined compared to untreated cells. Reduction
of cell viability was time and concentration dependent
Fig. 2 Effect of DOX on Jurkat cell viability by MTS assay. Cells
were cultured in the presence of different concentrations of DOX for
24, 48 and 72 h and viability was determined compared to untreated
cells. Reduction of cell viability was time and dose dependent
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observed at all used combinations compared to each drug
alone (Fig. 6). The results showed synergistic toxicity at 24
(data not illustrated) and 48 h. While 50% viability was
observed at 0.28 lM concentration of DOX and 16 lM of
TQ, a combination of 0.01 lM of DOX and 9 lM of TQ
caused 50% decrease in viability (Fig. 6b). CI (combina-
tion value) were represented in Table 1.
Discussion
Induction of apoptosis in cancer cells is an imperative
system of activity of some chemo-preventive agents [27].
Our study investigates the anti-proliferative and apoptosis
induction of TQ on a lymphoblastic Leukemia cell line. TQ
has already been shown to have very lower cytotoxicity on
Fig. 3 Concentration-dependent apoptosis induction by TQ in Jurkat
cells. Cells were exposed to TQ at the indicated concentrations and
incubated for 48 h. Apoptosis induction was assessed by flow
cytometry after annexin V-FITC/PI stating. a Each histogram the
levels of FITC fluorescence in each histogram. b Fluorescence curves
obtained for untreated and TQ-treated (16 lM) cells in one chart. The
data are representative of three independent experiments
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Fig. 4 Concentration-dependent effects of TQ on the number of
apoptotic cells, in Jurkat cells. Cells were exposed to different
concentration of TQ (4, 8, 12, 16 and 20 lM) for 48 h. Dot plots
shows the results of a representative apoptosis assay. Cells of the
lower left quadrant are viable (Q4); cells of the lower right quadrant
are in early apoptosis (Q3); cells of the upper left are in necrosis (Q1);
cells of the upper right are in late apoptosis (Q2). The number of cells
in apoptosis, expressed as percentage relative to the total cell number,
is indicated
Fig. 5 Effect of TQ on
apoptosis at various
concentration after 24, 48 and
72 h. Treated cells with TQ at
concentration of 12, 16 and
20 lM for 24 and 48 h and at 16
and 20 lM for 72 h incubation,
showed significant increase in
the amount of apoptotic cells
compared to control group
(*P\ 0.05, **P\ 0.01,
***P\ 0.001)
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normal PBMC than cancer cells [28, 29]. The anticancer
effects of TQ have been reported to be mediated through
various mechanisms such as anti-proliferation, apoptosis
induction, cell cycle arrest, ROS generation and anti-
metastasis/anti-angiogenesis [8]. Anti-proliferative effect
of TQ has been shown in various cell lines and tumors
[30–33] including drug resistant cell lines [30, 34].
Abdelfadil et al. [35] showed that TQ treatment of T28 oral
cancer decrease the viability in dose-dependent manner
which is consistent with our findings on Jurkat cells as we
had decrease of cell viability with increase of concentra-
tion. On the other hand TQ had significant cytotoxic con-
sequences for N28 non-tumor cells only at high
concentration (100 lM), while it was cytotoxic at dose of
50 lM for T28 cells [35]. Chern Chiuh Woo reported that
TQ can suppress the growth of various breast cancer cell
lines including MCF-7, MDA-MB-231 and BT-474. This
study showed the dose and time dependent anti-prolifera-
tive effect of TQ, and IC50 values for above cell lines were
32, 11 and 21 lM for 48 h, respectively [34]. To show the
anti-proliferative potency of TQ, some studies compared
this effect with chemotherapy drugs, as IC50 values against
Siha cells were 14.67 and 18.73 lM for TQ and cisplatin,
respectively, as Ng et al. reported [36]. Norfazlina et al.
[37] found that TQ can inhibit cell proliferation and
induces apoptosis in HL-60 cells (human myeloid
leukemia), and the inhibition concentration was about
19 lM, that is consistence with our findings. Our findings
showed that TQ can suppress cell proliferation with a time-
dependent manner as the IC50 was 19.461, 17.342 and
14.123 for 24, 48 and 72 h respectively. While TQ has
potent cytotoxic effects on cancer cells, it had a little effect
on normal cells including mouse fibroblasts (L929) [12],
prostate epithelial cells (BPH-1) [33], human normal
intestinal cells (FHs74Int) [38] and human normal lung
fibroblast cells (IMR90) [39], which is favorable for anti-
cancer therapy.
Doxorubicine like other DNA synthesis inhibitor agents
has very side effects that heart toxicity is the most
important of them. This drug is used in treatment of wide
range of cancers such as leukemia, lymphoma and solid
tumors and often used in combination with other drugs for
treatment of cancers in chemotherapy regimen [40]. In this
study the anti-proliferative effect of DOX on a lym-
phoblastic Leukemia cell line was investigated. Different
studies have reported the relationship between the con-
centration of the drug and cytotoxic effect, as a study on
breast cancer cells has shown that increasing the concen-
tration of the drug significantly increases the rate of cell
death [41]. Several studies demonstrated the effect of drug
concentration and treatment duration on various cancer
cells including endothelial cells, myocytes, lymphoblastic
leukemia cells [42, 43]. A study conducted by sakalar and
et al. [44] on T cells showed that doxorubicin lead to a
reduction in DNA replication by blocking the cells in G0/
G1 and also leads to cancer cell death by activating the
receptors Fas and caspase-dependent pathway. The results
of our study was in consistent with the results of other
studies.
TQ-induced apoptosis can be triggered by various
ways and targeting different proteins. Previous studies
Fig. 6 Jurkat cells were treated with different concentrations of TQ and DOX. A combination of DOX and TQ at 48 h, showed significant
reduction in cell viability compared to each drug alone
Table 1 Combination index values of DOX in combination with TQ
on the viability of jurkat cells
Concentration of drugs Time (h) CI value*
10 lM TQ ? 0.03 lM DOX 24 0.9263
9 lM TQ ? 0.01 lM DOX 48 0.9196
* CI = 1: additive effect, CI\ 1: synergism effect, CI[ 1: antago-
nism effect
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showed that induction of apoptosis by TQ can be caspase
cascade dependent, as in myeloblastic leukemia HL-60
[45], or independent, as in prostatic cancer cell line [46].
Our findings showed the TQ as a powerful apoptosis
inducer in jurkat cells. As shown in Fig. 3, following 24
and 48 h incubation, it derived almost all the cells to
apoptosis at 16 and 20 lM concentrations. The present
study demonstrated that apoptosis induced by TQ, fol-
lowed a time and dose dependent manner which is
consistent with our data for cell viability. The results of
our study are in agreement with the other works, showed
the apoptosis induction by TQ in some other cell lines
such as neuroblastoma [47], human myeloblastic leuke-
mia [31], human breast carcinoma [34, 48], human colon
cancer [38], hepatic cancer [49], and osteosarcoma cell
lines [50]. Hussain et al. [51] reported the apoptotic
effect of TQ in several primary effusion lymphoma
(PEL) in a dose-dependent manner which is again in
agreement with our study showed.
In examining the effects of DOX in combination with
TQ on viability of the cells, TQ effectively increases the
cytotoxic effects of doxorubicin that was very significant at
24 and 48 h. A combination of two drugs at IC50, signif-
icantly induce cytotoxic effects in cells, compare with each
drug alone at the same concentration. A study by Naus
et al. has shown that the combination of PolyFenol has a
synergistic effect with chemotherapy (gemcitabine, 5-flu-
orouracil and mitomycin). Such combinations can be used
to improve the efficacy of chemotherapy agents in the
treatment of cancer and to enhance the cytotoxic effect
given dose and to minimize side effects of the
chemotherapy drugs used as single compounds or can be
used as a dietary supplement with chemotherapy [52].
Another study demonstrated the effect of TQ along with
gemcitabine and oxaliplatine on the pancreas cells. The
results showed 2 and 3 times more cytotoxic effect in
combination of drugs with TQ than any of them alone [42].
The effect of the combination of TQ and DOX on T cell
lymphoblastic leukemia has not been investigated and our
data demonstrated the synergistic effect of the
combination.
Conclusion
The study demonstrated that TQ can induce apoptosis in
this lymphoblastic leukemia cell line which is a favorable
effect of anti-cancer therapy It was also shown that TQ
enhance the effects of doxorubicin on Jurkat cells. This
compound can be considered in combination with common
chemotherapy agents in vitro in other cell lines and ALL
lymphoblasts and experimental invivo models.
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